We are live on ! Find out more
GCTK icon

GlucoTrack

8 hedge funds and large institutions have $594K invested in GlucoTrack in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding

Funds holding: 48 (+4)

0% more ownership

Funds ownership: 0%0% (+0%)

20% less capital invested

Capital invested by funds: $743K → $594K (-$149K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
8
Holders Change
+4
Holders Change %
+100%
% of All Funds
0.13%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
4
Increased
Reduced
1
Closed
Calls
Puts
Net Calls
Net Calls Change

GCTK Hedge Fund Activity: Q3 2023 in Review

8 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in GlucoTrack (GCTK) for Q3 2023, worth a combined $594K — down 20% from $743K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new GCTK positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Boston Financial Management, opening a new position worth an estimated $16.2K. The largest seller was Sabby Management, cutting an estimated $8.98K.

  • 8 institutional investors held GlucoTrack (GCTK) as of Q3 2023, up from 4 in Q2 2023.
  • Funds reported $594K of GlucoTrack stock for Q3 2023, down 20% quarter-over-quarter.
  • 4 funds opened new GlucoTrack positions in Q3 2023 and 0 closed out, a net change of +4 holders.
  • The largest GlucoTrack buyer in Q3 2023 was Boston Financial Management, an estimated $16.2K added.
  • The largest GlucoTrack seller in Q3 2023 was Sabby Management, an estimated $8.98K sold.

Based on aggregated 13F filings for Q3 2023.